Telesis Bio Inc. TBIO
0.00
(0.01)
(100.00%)
as of 25 Sep
- Market cap
- $5.3M
- P/E
- 0.0×
Follow TBIO
Growth Flags
show if company had growth for consecutive years
| Sep '24 | Jun '24 | Mar '24 | Dec '23 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.41 | 0.35 | 0.53 | 0.43 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(0.98) | (1.25) | (4.05) | (1.61) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 49.44 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.51 | 0.09 | 0.11 | (0.08) | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.07 | |
EV/Operating CF |
(0.37) | (0.08) | (0.10) | 0.06 | |
EV/FCF |
(0.35) | (0.08) | (0.10) | 0.06 | |
Quick Ratio |
0.89 | 1.45 | 2.92 | 3.02 | |
Current Ratio |
1.23 | 1.89 | 3.65 | 3.71 | |
Net Debt/EBITDA |
(0.35) | 0.46 | 1.42 | 2.46 | |
Debt/Assets |
25.19% | 10.21% | 8.44% | 7.69% | |
Debt/Equity |
(0.23) | (0.26) | (0.65) | 22.76 | |
Asset Turnover |
0.26 | 0.23 | 0.32 | 0.36 | |
Operating CF/Net income |
0.96 | 0.41 | 0.35 | 0.40 | |
Capex/Depreciation |
(0.07) | (0.09) | (0.41) | (0.03) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
138.83% | 159.35% | 85.03% | 50.78% | |
Selling, General and Administrative Expense of Revenue |
254.09% | 464.84% | 204.71% | 80.98% | |
Intangible Assets out of Total Assets |
0.17 | 0.08 | 0.07 | 0.06 | |
Share Based Compensation of Revenue |
36.14% | 56.06% | 22.27% | 6.10% | |
Graham Net Nets |
(6.46) | (8.70) | (3.68) | (3.38) | |
Graham Number |
98.70 | 90.65 | 55.90 | 0.00 | |
Earnings Yield |
(736.32%) | (797.04%) | (359.46%) | (413.49%) | |
Free Cash Flow Yield |
(351.16%) | (341.10%) | (219.33%) | (311.30%) | |
Revenue per Share |
0.88 | 0.90 | 2.06 | 6.08 | |
Operating CF per Share |
(3.92) | (3.09) | (1.94) | (4.42) | |
Capex per Share |
(0.03) | (0.05) | (0.30) | (0.20) | |
Free Cash Flow per Share |
(3.96) | (3.14) | (2.24) | (4.62) | |
Cash per Share |
2.60 | 5.96 | 9.39 | 11.65 | |
Shareholders Equity per Share |
(15.35) | (11.87) | (4.93) | 0.14 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(15.35) | (11.87) | (4.93) | 0.14 | |
Free Cash Flow |
(7.01) | (5.43) | (3.74) | (7.67) | |
Working Capital |
1.49 | 7.14 | 16.98 | 22.17 | |
Capital Expenditures |
(0.05) | (0.08) | (0.50) | (0.34) | |
Net Current Asset Value |
(43.84) | (58.11) | (48.17) | (39.82) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.05 | |
Capex to Sales |
0.04 | 0.05 | 0.15 | 0.03 | |
Net Profit Margin |
(463.41%) | (850.39%) | (268.08%) | (181.01%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
3.31 | 4.79 | 4.42 | 5.63 | |
Average Payables |
1.95 | 1.48 | 2.17 | 2.23 | |
Average Inventory |
2.68 | 2.61 | 2.98 | 2.96 | |
Average Assets |
64.88 | 83.63 | 76.25 | 75.89 | |
Average Common Equity |
(4.73) | 3.69 | 14.19 | 23.40 |
Columns are period end dates